SINOVAC BIOTECH LTD
corporate_fare Company Profile
SINOVAC BIOTECH LTD (NASDAQ:SVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for SVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-17, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for SVA spans 6-K, 20-F, SCHEDULE 13D/A.
Recent high-impact activity:
- Sinovac H1 Revenue Jumps 13% on 82% Overseas Sales Surge
- Sinovac H1 2026: Revenue Up 13%, Net Loss Widens to $60.2M; Rabies Vaccine Approved
- Sinovac Biotech Regains Nasdaq Compliance, Averting Delisting
- Sinovac Biotech Reports $59.7M Net Loss for 2025, $202.8M Impairments, and $3.3B Special Dividend
- Sinovac Biotech Files 20-F with Adverse Auditor Opinion on Internal Controls, Faces Nasdaq Delisting
Financial Snapshot
Short Interest & Short Volume
FINRA reported short interest of 82,156 shares in SVA as of the September 15, 2026 settlement, unchanged from the prior period.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
SVA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.